In medicine discovery, identifying the right biological target has always been a critical and complex step. Today, the rise of powerful screening tools is fundamentally reshaping this process, ...
第8届世界PFIC认知日：提高疾病认知、推动早诊早治，让患儿家庭不再独自前行 每年10月5日是世界PFIC认知日（World PFIC Awareness Day），这一疾病日由国际患者组织发起，旨在呼吁社会各界关注进行 ...
PFIC is a group of rare inherited liver conditions that affects the body's ability to transport and circulate bile, which is essential for digesting and absorbing fats, as well as removing waste ...
BARCELONA, ESPAÑA, 10 de septiembre 2026.-Ipsen (Euronext: IPN; ADR: IPSEY) ha presentado hoy, junto con la Asociación para la lucha contra las enfermedades biliares inflamatorias (ALBI España) y la ...
Navtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to ruxolitinib for patients with myelofibrosis who have a suboptimal response to ruxolitinib. The Phase III ...
PARIS, FRANCE, 24 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have ...
Every scientific breakthrough begins with a question: can this medicine extend life, restore balance, or meaningfully change what is possible for patients? At Ipsen, we are bringing that same ...
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and ...
Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in ...
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...
Progressive Familial Intrahepatic Cholestasis (PFIC) can be a complex condition. Finding trusted information about PFIC shouldn’t be. PFIC Colors is designed to help families make sense of these ...
Acute myeloid leukaemia (AML) remains a difficult blood cancer to treat. Despite progress, relapse is still common and long-term disease control remains out of reach for many, especially older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results